Stock OCS OCULIS HOLDING AG
Add to a list
To use this feature you must be a member
Log inSign up

All News Oculis Holding AG

Equities

OCS

CH1242303498

End-of-day quote Nasdaq
Other stock markets
 06:00:00 2024-05-21 pm EDT 		5-day change 1st Jan Change
11.9 USD 0.00% Intraday chart for Oculis Holding AG -0.92% +5.97%
May. 08 Oculis Holding AG Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 24 H.C. Wainwright Adjusts Price Target on Oculis Holding to $28 From $29, Keeps Buy Rating MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Oculis Holding - Increase in share capital
AQ
Oculis updates share capital for its existing at-the-market offering program
GL
Oculis : Entry into Sales Agreement with Leerink Partners, LLC - Form 6-K
PU
Oculis : Form 6-K
PU
Oculis Reports Q1 2024 Financial Results and Provides Company Updates
GL
Oculis Holding AG Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Oculis Announces Completion of Enrollment in Phase 2 Randomized Controlled ACUITY Trial with OCS-05 for Acute Optic Neuritis
AQ
Oculis Publishes Invitation to the Annual General Meeting
GL
Oculis to Present at Bank of America Global Healthcare Conference
AQ
Oculis Publishes Invitation to the Annual General Meeting
AQ
H.C. Wainwright Adjusts Price Target on Oculis Holding to $28 From $29, Keeps Buy Rating
MT
Oculis Holding AG(NasdaqGM:OCS) added to OMX Nordic All-Share Index
CI
Oculis Completes $59 Million Direct Offering of Shares
MT
Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market
GL
Oculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Market
AQ
Oculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as President of Research & Development
AQ
Oculis Holding AG Strengthens its Executive Leadership Team with the Appointment of Snehal Shah as President of Research & Development
CI
Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
AQ
Oculis Holding Ag Announces Positive Results from Phase 3 Optimize-1 Trial of Once Daily Ocs-01 for the Treatment of Inflammation and Pain Following Cataract Surgery
CI
Oculis to Participate at Upcoming April Investor Conferences
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. OCS Stock
  4. News Oculis Holding AG